- BXRX is a currently discounted analgesia company that suffered from reduced demand due to COVID-19 pressure on elective surgeries.
- The company currently has an FDA-approved post-op analgesic that is favored by anesthesiologists, as well as a focused pipeline that could push it to the forefront of non-opioid analgesia companies.
- Should the company successfully ramp up ANJESO sales and market existing pipeline candidates, hitting more than 2x the current share price is not at all unreasonable.
For further details see:
Baudax Bio: A Potential Diamond In The Rough